Recent Posts
- Eyenovia to Present at Upcoming H.C. Wainwright 25th Annual Global Investment Conference September 7, 2023
- Eyenovia Acquires U.S. Commercial Rights To APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) From Formosa Pharmaceuticals August 16, 2023
- Eyenovia Announces First Commercial Sale of MydCombi™ August 3, 2023
Pipeline and Technology
Corporate Address
Eyenovia, Inc.
295 Madison Avenue
Suite 2400
New York, NY 10017
admin@eyenovia.com